within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AA22_Abetimus;
model Abetimus 
   extends Pharmacolibrary.Drugs.ATC.L.L04AA22;

  annotation(Documentation(
    info ="<html><body><p>Abetimus is a synthetic double-stranded oligonucleotide that acts as an immunosuppressive agent by inhibiting the production of anti-double stranded DNA antibodies. It was developed for the treatment of systemic lupus erythematosus (SLE) but was never approved, and its development has been discontinued.</p><h4>Pharmacokinetics</h4><p>Estimated PK parameters based on pharmacological class and physicochemical properties, as no published clinical pharmacokinetic data are available for abetimus in humans.</p><h4>References</h4><ol><li><p>Linnik, MD, et al., &amp; Crowther, MA (2008). Pharmacokinetics of high-dose abetimus sodium in normal subjects with specific assessment of effect on coagulation. <i>Journal of clinical pharmacology</i> 48(8) 909â€“918. DOI:<a href=&quot;https://doi.org/10.1177/0091270008319465&quot;>10.1177/0091270008319465</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18511650/&quot;>https://pubmed.ncbi.nlm.nih.gov/18511650</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Abetimus;
